Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 6:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Active Metabolic Product 1 Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

High-fat Meal Challenge in Pediatrics

NCT05230433
View directory record Official record
Conditions
Pediatric Obesity, Insulin Resistance
Interventions
High-fat Challenge
Dietary Supplement
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
8 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 21, 2026, 6:56 AM EDT
Not listed Phase 4 Interventional

Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus

NCT04027023
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Diabetes mellitus Type 2 De-escalation treatment (DET)
Drug
Lead sponsor
Sciema UG
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 21, 2026, 6:56 AM EDT
Recruiting Early Phase 1 Interventional

Regulation of Brain Glucose Metabolism in Type 1 Diabetes

NCT05317455
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Hypoglycemia Unawareness
Interventions
Dichloroacetate
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 21, 2026, 6:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Almased Multi-Center Diabetes Intervention Trial

NCT01702012
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Almased Meal Replacement Powder, Group-Based Lifestyle Intervention
Dietary Supplement · Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Sep 21, 2026, 6:56 AM EDT
Completed Phase 3 Interventional Results available

Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency

NCT01007071
View directory record Official record
Conditions
Hypopituitarism
Interventions
Human Growth Hormone (1-134), Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 21, 2026, 6:56 AM EDT
Withdrawn Phase 4 Interventional

Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.

NCT03640221
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
Ertugliflozin, Hydrochlorothiazide 12.5mg, Microneurography, SKNA recordings, Static Handgrip, Post-handgrip forearm vascular occlusion, Testing of the Arterial Baroreflex Function
Drug · Device · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
35 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 21, 2026, 6:56 AM EDT
Completed Phase 4 Interventional

Solriamfetol and CBT-I in Patients With Insomnia Disorder

NCT05838430
View directory record Official record
Conditions
Insomnia
Interventions
Solriamfetol 75 MG, Cognitive Behavioral Therapy for Insomnia (CBT-I), Monitoring, Placebo
Drug · Behavioral · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
25 Years to 60 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 21, 2026, 6:56 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Sildenafil Citrate on Insulin Resistance in African American

NCT01334554
View directory record Official record
Conditions
Metabolic Syndrome, Obesity
Interventions
Sildenafil, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 21, 2026, 6:56 AM EDT
Terminated Phase 3 Interventional Results available

Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes

NCT00288353
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
aripiprazole (Abilify), ziprasidone (Geodon)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 21, 2026, 6:56 AM EDT
Completed Phase 1 Interventional

Endoxifen in Adults With Hormone Receptor Positive Solid Tumors

NCT01273168
View directory record Official record
Conditions
Hormone Receptor-Positive Breast, Gynecologic, Desmoid, Hormone Receptor-Positive Neoplasms
Interventions
Z-Endoxifen
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 21, 2026, 6:56 AM EDT
Withdrawn Phase 2 Interventional

Mechanisms of Metabolic Regulation of Resveratrol on Humans With Metabolic Syndrome

NCT00654667
View directory record Official record
Conditions
Insulin Resistance
Interventions
Placebo, Resveratrol
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Sep 21, 2026, 6:56 AM EDT
Completed Phase 1 Interventional

VRS-317 in Adult Subjects With Growth Hormone Deficiency

NCT01359488
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
VRS-317
Drug
Lead sponsor
Versartis Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2012 · Synced Sep 21, 2026, 6:56 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Precision Functional Brain Mapping in Psilocybin

NCT04501653
View directory record Official record
Conditions
Psilocybin
Interventions
Psilocybin, Methylphenidate
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 40 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 21, 2026, 6:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics

NCT02286622
View directory record Official record
Conditions
Renal Impairment
Interventions
Deflazacort
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 21, 2026, 6:56 AM EDT
Completed Phase 3 Interventional

Treatment of Lead-Exposed Children Trial

NCT00342849
View directory record Official record
Conditions
Lead Exposure
Interventions
Succimer, Placebo
Drug
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
12 Months to 33 Months
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2015
U.S. locations
4
States / cities
Baltimore, Maryland • Newark, New Jersey • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 21, 2026, 6:56 AM EDT
Completed Phase 1 Interventional

The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists

NCT03049462
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Mirabegron, B Complex Plus Vitamin C Tablets
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 40 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 21, 2026, 6:56 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

NCT03301350
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer
Interventions
Carboplatin, Paclitaxel, Doxorubicin, Cyclophosphamide, Pegfilgrastim, Filgrastim
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 74 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Rockford, Illinois • Madison, Wisconsin • Milwaukee, Wisconsin + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 21, 2026, 6:56 AM EDT
Active, not recruiting No phase listed Observational

Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

NCT07188545
View directory record Official record
Conditions
Cardiovascular Kidney Metabolic Syndrome
Interventions
Intervention, Active Comparator
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
23,280,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 21, 2026, 6:56 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Assessing the Impact of Contraceptives on Bone Health Using 41Ca

NCT02367846
View directory record Official record
Conditions
Other Disorders of Bone Development and Growth
Interventions
Combined Oral Contraceptive (COC), Contraceptive Vaginal Ring (CVR)
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2028
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 21, 2026, 6:56 AM EDT
Terminated Phase 2 Interventional Results available

Pembro+Chemo in Brain Mets

NCT04964960
View directory record Official record
Conditions
Lung Cancer, Lung Cancer Metastatic, Brain Cancer, Cancer
Interventions
Pembrolizumab, Nab paclitaxel, Paclitaxel, Pemetrexed, Carboplatin
Drug
Lead sponsor
John L. Villano, MD, PhD
Other
Eligibility
18 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 21, 2026, 6:56 AM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects

NCT05653258
View directory record Official record
Conditions
Obesity, Healthy Lifestyle
Interventions
Lifestyle Intervention, Dasatinib 100 MG, Quercetin 1000mg, Placebo, Abdominal adipose tissue biopsy
Other · Drug · Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 21, 2026, 6:56 AM EDT
Completed Phase 2 Interventional

R33: Levetiracetam in Early Psychosis

NCT04317807
View directory record Official record
Conditions
Early Psychosis
Interventions
Levetiracetam Pill, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 40 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 21, 2026, 6:56 AM EDT
Terminated Phase 2 Interventional

To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia

NCT04311515
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Tau Positron emission tomography (PET), Fluorodeoxyglucose (FDG) Positron emission tomography (PET), Cerebrospinal fluid (CSF) Biomarkers, Blood Biomarkers, Rating Scales, PU-AD, Placebo
Radiation · Diagnostic Test · Behavioral + 1 more
Lead sponsor
Samus Therapeutics, Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Boca Raton, Florida • Delray Beach, Florida • Lake Worth, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Sep 21, 2026, 6:56 AM EDT
Recruiting Early Phase 1 Interventional

Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence

NCT02446431
View directory record Official record
Conditions
Solid Tumor
Interventions
Bevacizumab, Cyclophosphamide, Valproic Acid, Temsirolimus
Drug
Lead sponsor
Miller Children's & Women's Hospital Long Beach
Other
Eligibility
12 Months to 31 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
2
States / cities
Long Beach, California • Orange, California
Source: ClinicalTrials.gov public record
Updated May 17, 2015 · Synced Sep 21, 2026, 6:56 AM EDT